Sault Area Hospital (SAH) is now offering Xofigo, a novel treatment for advanced prostate cancer.
Funded by Cancer Care Ontario, Xofigo is a radiopharmaceutical intravenous (IV) injection used to treat symptomatic prostate cancer that is resistant to medical or surgical treatments and has spread to bones but not to other organs. “For some patients, this new drug therapy will provide pain relief, improve quality of life and increase overall survival rates,” says Dr. Silvana Spadafora, Chief Oncologist at SAH.
The Algoma District Cancer Program at SAH is the first facility in the Northeast to treat patients using this innovative therapy. “Xofigo fulfills an unmet need in our community which was not previously available,” says Dr. Spadafora. The treatment is available at SAH through a unique partnership between the hospital’s Diagnostic Imaging department and the Algoma District Cancer Program. Since radiopharmaceuticals are drugs that contain radioactive materials, Xofigo must be administered by a qualified, licensed technician in the nuclear medicine department.
To date, three SAH patients have received the first injection of a 6-month treatment regimen. “The treatment is quick, safe, non-invasive, painless and has few side effects,” says Dr. Spadafora. “This is good news because patients who would benefit from this treatment can now receive it close to home.”
To find out more about SAH, visit: www.sah.on.ca